Second-generation antipsychotics for the treatment of disruptive behaviour disorders in children: A systematic review

Canadian Journal of Psychiatry

Volumn 57, Issue 12, 2012, Pages 722-727

  Pringsheim, Tamara ^a,b   Gorman, Daniel ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b ALBERTA CHILDREN'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Attentiondeficit hyperactivity disorder; Children; Conduct disorder; Disruptive behaviour disorders; Oppositional defiant disorder; Second generation antipsychotics

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; PLACEBO; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADOLESCENT; AGGRESSION; AGITATION; ATTENTION DEFICIT DISORDER; CHILD; CHILD PSYCHIATRY; CLINICAL PRACTICE; CONDUCT DISORDER; CULTURAL FACTOR; DISRUPTIVE BEHAVIOR; DRUG EFFICACY; DRUG INDUSTRY; EVENING DOSAGE; HOSTILITY; HUMAN; HYPERACTIVITY; INTELLIGENCE QUOTIENT; IRRITABILITY; JUVENILE; LOW DRUG DOSE; MORNING DOSAGE; OPPOSITIONAL DEFIANT DISORDER; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84873853309     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371205701203     Document Type: Review

References (30)

1. Pringsheim T, Lam D, Patten SB. The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005-2009. J Child Adolesc Psychopharmacol. 2011;21(6):537-543.
2. Olfson M, Blanco C, Liu L, et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63(6):679-685.
3. Pringsheim T, Panagiotopoulos C, Davidson J, et al. Evidencebased recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry. 2011;20(3):218-233.
4. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: A review of the process. Am J Prev Med. 2001;20(3 Suppl):21-35.
5. Pringsheim T, Lam D, Ching H, et al. Metabolic and neurological complications of second-generation antipsychotic use in children. A systematic review and meta-analysis of randomized controlled trials. Drug Saf. 2011;34(8):651-668.
6. Van Bellinghen M, De Troch C. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: A double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol. 2001;11(1):5-13.
7. Aman M, De Smedt G, Derivan A, et al. Double-blind, placebocontrolled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002;159(8):1337-1346.
8. Buitelaar J, van der Gaag R, Cohen-Kettenis P, et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry. 2001;62(4):239-248.
9. Reyes M, Buitelaar J, Toren P, et al. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry. 2006;163(3):402-410.
10. Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(5):558-565.
11. Findling RL, McNamara NK, Branicky LA, et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry. 2000;39(4):509-516.
12. Connor DF, McLaughlin TJ, Jeffers-Terry M. Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. J Child Adolesc Psychopharmacol. 2008;18(2):140-156.
13. Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry. 2002;41(9):1026-1036.
14. [The MTA Cooperative Group]. A 14-month randomized clinical trial of treatment strategies for attention-deficit/ hyperactivity disorder. The MTA Cooperative Group. Multimodel Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999;56(12):1073-1086.
15. Connor DF, Glatt SJ, Lopez ID, et al. Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry. 2002;41(3):253-261.
16. Blader JC, Pliszka SR, Jensen PS, et al. Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD. Pediatrics. 2010;126(4):e796-e806.
17. Cooper W, Arbogast P, Ding H, et al. Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr. 2006;6(2):79-83.
18. Crystal S, Olfson M, Huang C, et al. Broadened use of atypical antipsychotics: Safety, effectiveness, and policy challenges. Health Aff (Millwood). 2009;28(5):w770-w781.
19. Olfson M, Crystal S, Huang C, et al. Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry. 2010;49(1):13-23.
20. Alessi-Severini S, Biscontri RG, Collins DM, et al. Ten years of antipsychotic prescribing to children: A Canadian population-based study. Can J Psychiatry. 2012;57(1):52-58.
21. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765-1773.
22. Pfeiffer D, Brule-Brown D. Second-generation antipsychotics and cardiometabolic adverse reactions in children and adolescents. Canadian Adverse Reaction Newsletter. 2012;22(1):1-2.
23. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314-321.
24. Doey T, Handelman K, Seabrook JA, et al. Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients aged under 18 years. Can J Psychiatry. 2007;52(6):363-368.
25. Morrato EH, Druss B, Hartung DM, et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry. 2010;67(1):17-24.
26. Pappadopulos E, Rosato NS, Correll CU, et al. Experts' recommendations for treating maladaptive aggression in youth. J Child Adolesc Psychopharmacol. 2011;21(6):505-515.
27. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med. 1982;73(7):4-8.
28. Spielmans GI, Parry PI. From evidence-based medicine to marketing-based medicine: Evidence from internal industry documents. J Bioeth Inq. 2010;7(1):13-29.
29. Jensen PS. The role of psychosocial therapies in managing aggression in children and adolescents. J Clin Psychiatry. 2008;69(Suppl 4):37-42.
30. Fossum S, Handegård BH, Martinussen M, et al. Psychosocial interventions for disruptive and aggressive behaviour in children and adolescents. Eur Child Adolesc Psychiatry. 2008;17(7):438-451.